ArticleInflammation2016
Serum Cystatin C as an Inflammatory Marker in Exacerbated and Convalescent COPD Patients.
Article in Inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between cystatin C and COPD: a meta-analysis and systematic review.BMC pulmonary medicine · 2020Pooled it
- Different eGFR markers and prediction of cardiovascular risk.Journal of internal medicine · 2026Trial
- Comprehensive proteome profiling of molecular endotypes in Japanese adults with moderate-to-severe atopic dermatitis.Frontiers in medicine · 2025Article
- Peripheral Blood NMLR Can Predict 5-Year All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Article
- Inflammation and Nutritional Status Mediated the Increased of Risk of Atrial Fibrillation Recurrence Associated with eGFRdiff Post-Ablation.Journal of inflammation research · 2024Article
- Serum creatinine/cystatin C ratio is a surrogate marker for sarcopenia in patients with idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2022Article
- Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients.Renal failure · 2021Article
- Effects of dexmedetomidine on immune function, renal function and inflammatory factors of patients undergoing percutaneous nephrolithotomy under general anesthesia.Experimental and therapeutic medicine · 2021Article
- Characterization of a Murine Model of Oxazolone-Induced Orbital Inflammation.Translational vision science & technology · 2020Article
- Utility of the Serum Cystatin C Level for Diagnosis of Osteoporosis among Middle-Aged and Elderly People.BioMed research international · 2019Article
- Serum Cystatin C Levels in COPD: Potential Diagnostic Value and Relation between Respiratory Functions.Journal of medical biochemistry · 2018Article
- Cystatin F as a regulator of immune cell cytotoxicity.Cancer immunology, immunotherapy : CII · 2018Review
- The clinical implication of serum cyclophilin A in patients with chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2018Article
- Optimally predicting mortality with kidney function markers is not the same as optimally determining how kidney function predicts mortality.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Article
- Association of cathepsin B and cystatin C with an age-related pulmonary subclinical state in a healthy Chinese population.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease with high morbidity and mortality rates. Cystatin C (Cys C) is a sensitive indicator for various chronic inflammatory diseases. In this study, we aimed to evaluate the role of Cys C in COPD patients comparing with the other well-known inflammatory markers. Ninety patients with acute exacerbated COPD were studied and were reassessed when convalescent. Ninety controls were matched for age, gender, body mass index, smoking index, and comorbidity. Serum Cys C was significantly increased in convalescent COPD patients compared with healthy controls and further increased in COPD patients with an acute exacerbation. Serum Cys C was positively correlated with hsCRP both in the exacerbation and convalescence periods of COPD and negatively correlated with FEV1% predicted and FEV1/FVC in the convalescent COPD patients. In conclusion, serum Cys C is a positive acute-phase reactant in COPD patients and might indicate systemic inflammation during the progression of COPD.
Indexed as
Identifiers
26613760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.